Akebia Therapeutics/$AKBA
About Akebia Therapeutics
Ticker
Industry
Employees
AKBA Metrics
$408M
-
-$0.23
0.70
-
Price and volume
Market cap
$408M
Beta
0.7
52-week high
$2.48
52-week low
$0.80
Average daily volume
2.1M
Financial strength
Current ratio
1.524
Quick ratio
1.007
Long term debt to equity
-189.82
Total debt to equity
-204.748
Interest coverage (TTM)
-2.61%
Management effectiveness
Return on assets (TTM)
-9.37%
Return on equity (TTM)
102.40%
Valuation
Price to revenue (TTM)
2.243
Price to book
-7.85
Price to tangible book (TTM)
-3.34
Price to free cash flow (TTM)
-9.888
Growth
Revenue change (TTM)
-12.53%
Earnings per share change (TTM)
-28.49%
3-year revenue growth (CAGR)
-6.92%
3-year earnings per share growth (CAGR)
-50.52%
What the Analysts think about AKBA
Analyst Ratings
AKBA Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
AKBA Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
AKBA News
FAQs
What’s the current market cap for Akebia Therapeutics stock?
What is the P/E ratio for Akebia Therapeutics stock?
Does Akebia Therapeutics stock pay dividends?
No, Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Akebia Therapeutics dividend payment date?
Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders.
What is the beta indicator for Akebia Therapeutics?
Akebia Therapeutics (AKBA) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.